Clinical features and management of iris melanoma - a systematic review
DOI:
https://doi.org/10.12775/JEHS.2022.12.08.043Keywords
iris, melanoma, uveaAbstract
Introduction and purpose
Uveal melanoma is the most common primary intraocular malignancy in adults. Most of them arise in the choroid and ciliary body, whereas 2-5 % of the cases are located to the iris. Nevertheless, during the last few decades the incidence of this neoplasm has been increasing. The aim of the study is to discuss the risk factors, clinical features and methods of diagnosis and treatment of iris melanoma.
Description of the state of knowledge
Iris melanomas vary in their shape, size, degree of pigmentation and clinical behavior and most commonly present as a nodular tumor located in the lower temporal iris quadrant. This localisation is linked to exposure to solar radiation, which among light-colored iris, skin color and pre- existing iris naevus, is a risk factor for this malignancy. Gender predilection for the development of iris melanoma is unclear, however, some studies indicate a predominance of female patients. The most common clinical symptoms are growth of a pre-existing naevus, detection of new, dark lesion, pain secondary to elevated IOP and blurred vision. Due to anterior location of this site of uvea, early diagnosis and treatment is possible. Slit-lamp examination, gonioscopy, and ultrasound biomicroscopy (UBM) allow staging of the tumor to guide the most appropriate treatment. As many primary iris lesions have a benign prognosis, surgical resection or radiotherapy is efficient way of treatment and allows good local tumor control.
Summary
Iris melanoma is least frequent of all uveal melanomas and usually presents as variably pigmented, elevated, solitary lesion. When there is a clinical suspicion of malignancy slit- lamp examination and UBM should be performed. When early diagnosed it can be successfully treated.
References
Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013 Jun 15;6(7):1230-44. PMID: 23826405; PMCID: PMC3693189.
Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998 Oct 15;83(8):1664-78. doi: 10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g. PMID: 9781962.
Krohn J, Sundal KV, Frøystein T. Topography and clinical features of iris melanoma. BMC Ophthalmol. 2022 Jan 3;22(1):6. doi: 10.1186/s12886-021-02236-3. PMID: 34980044; PMCID: PMC8725464.
Russo A, Avitabile T, Reibaldi M, Bonfiglio V, Pignatelli F, Fallico M, Caltabiano R, Broggi G, Russo D, Varricchio S, Spatola C, Basile A, Liardo RLE, Milazzotto R, Arena F, Foti PV, Longo A. Iris Melanoma: Management and Prognosis. Appl. Sci. 2020; Oct (24):8766. https://doi.org/10.3390/app10248766
Singh AD, Damato BE. Iris Melanoma. Clinical Ophthalmic Oncology. Springer, Cham. 2019:155–184 https://doi.org/10.1007/978-3-030-17879-6_10
Shields CL, Kels JG, Shields JA. Melanoma of the eye: revealing hidden secrets, one at a time. Clin Dermatol. 2015 Mar-Apr;33(2):183-96. doi: 10.1016/j.clindermatol.2014.10.010. Epub 2015 Jan 14. PMID: 25704938.
McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005 Mar 1;103(5):1000-7. doi: 10.1002/cncr.20866. PMID: 15651058.
Nagarkar R, Roy S, Wagh A, Kokane G, Adhav A, Pawar S. Ocular melanoma: A rare entity. J Head Neck Physicians Surg 2019;7:79-81
Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, Mehta S, Forte L, Long A, Dellacava EF, Kaplan B, Shields JA. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009 Aug;127(8):989-98. doi: 10.1001/archophthalmol.2009.208. PMID: 19667335.
Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, de Keizer RJ, Sandkull P, Seregard S, Gologorsky D, Schefler AC, Murray TG, Kivelä T, Giuliari GP, McGowan H, Simpson ER, Corriveau C, Coupland SE, Damato BE. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012 Jan;130(1):57-64. doi: 10.1001/archophthalmol.2011.286. Epub 2011 Sep 12. PMID: 21911649.
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM, Paci E; EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007 Dec;114(12):2309-15. doi: 10.1016/j.ophtha.2007.01.032. Epub 2007 May 11. PMID: 17498805.
Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009 Sep;93(9):1129-31. doi: 10.1136/bjo.2008.150292. PMID: 19704035.
Nayman T, Bostan C, Logan P, Burnier MN Jr. Uveal Melanoma Risk Factors: A Systematic Review of Meta-Analyses. Curr Eye Res. 2017 Aug;42(8):1085-1093. doi: 10.1080/02713683.2017.1297997. Epub 2017 May 11. PMID: 28494168.
Weis E, Shah CP, Lajous M, Shields JA, Shields CL. The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis. Ophthalmology. 2009 Mar;116(3):536-543.e2. doi: 10.1016/j.ophtha.2008.10.008. Epub 2009 Jan 22. PMID: 19167086.
Harbour JW. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res. 2012 Mar;25(2):171-81. doi: 10.1111/j.1755-148X.2012.00979.x. Epub 2012 Feb 13. PMID: 22268848; PMCID: PMC4470256.
Mensink HW, Vaarwater J, de Keizer RJ, de Wolff-Rouendaal D, Mooy CM, de Klein A, Paridaens D. Chromosomal aberrations in iris melanomas. Br J Ophthalmol. 2011 Mar;95(3):424-8. doi: 10.1136/bjo.2010.181289. Epub 2010 Sep 29. PMID: 20881029.
Karimi S, Pahlevani P. Tapioca Melanoma of the Iris: A Case Report. J Ophthalmic Vis Res. 2019 Jul 18;14(3):376-381. doi: 10.18502/jovr.v14i3.4794. PMID: 31660116; PMCID: PMC6815328.
Houtzagers LE, Wierenga APA, Ruys AAM, Luyten GPM, Jager MJ. Iris Colour and the Risk of Developing Uveal Melanoma. Int J Mol Sci. 2020 Sep 28;21(19):7172. doi: 10.3390/ijms21197172. PMID: 32998469; PMCID: PMC7583924.
Schwab C, Mayer C, Zalaudek I, Riedl R, Richtig M, Wackernagel W, Hofmann-Wellenhof R, Richtig G, Langmann G, Tarmann L, Wedrich A, Richtig E. Iris Freckles a Potential Biomarker for Chronic Sun Damage. Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO174-BIO179. doi: 10.1167/iovs.17-21751. PMID: 28715582.
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017 Feb;31(2):241-257. doi: 10.1038/eye.2016.275. Epub 2016 Dec 2. PMID: 27911450; PMCID: PMC5306463.
Shields CL, Kaliki S, Hutchinson A, Nickerson S, Patel J, Kancherla S, Peshtani A, Nakhoda S, Kocher K, Kolbus E, Jacobs E, Garoon R, Walker B, Rogers B, Shields JA. Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide. Ophthalmology. 2013 Apr;120(4):766-72. doi: 10.1016/j.ophtha.2012.09.042. Epub 2013 Jan 3. PMID: 23290981.
Hau SC, Papastefanou V, Shah S, Sagoo MS, Restori M, Cohen V. Evaluation of iris and iridociliary body lesions with anterior segment optical coherence tomography versus ultrasound B-scan. Br J Ophthalmol. 2015 Jan;99(1):81-6. doi: 10.1136/bjophthalmol-2014-305218. Epub 2014 Aug 4. PMID: 25091953; PMCID: PMC4283679.
Rahmi A, Mammar H, Thariat J, Angellier G, Herault J, Chauvel P, Kodjikian L, Denis P, Grange JD. Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases. Graefes Arch Clin Exp Ophthalmol. 2014 Sep;252(9):1515-21. doi: 10.1007/s00417-014-2735-y. Epub 2014 Jul 20. PMID: 25038910.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Dominika Sereda, Hubert Nieścior, Aleksandra Metelska, Jakub Metelski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 380
Number of citations: 0